37
total announcements
APLLTD.NS · 15 min delayed
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the schedule of one-to-one meetings with investors/analysts on September 1-2, 2026, in Mumbai and virtually.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the schedule of one-to-one meetings with investors/analysts on September 1-2, 2026, in Mumbai and virtually.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about a newspaper advertisement related to notice of loss of equity share certificate(s) published in Indian Express and Financial Express on 25th August, 2026. The company is warning the public against purchasing or dealing with these equity shares certificates and is requesting claimants to send full details with documentary evidence to the company's RTA or the company within 15 days from the date of publication.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the appointment of Mr. Chirag Shukla as the new Company Secretary & Compliance Officer, effective August 20, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the opening of another special window for transfer and dematerialization of physical securities, as per SEBI Circular No. H0/38/13/11 (2)2026-MIRSD-POD/1/3750/2026 dated 31st January, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange regarding the resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer, effective August 10, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has reported a strong Q1 FY27 with 26% year-on-year revenue growth, driven by growth across all major businesses, including a 7% growth in India branded business, 37% growth in International Generics, and 33% growth in API business. The company has also strengthened its execution leadership with the appointment of Mr. Ramesh Juneja as Sales and Marketing Head for Human Health business.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has submitted the Exchange a copy of the Scrutinizers' report of the 16th Annual General Meeting held on August 05, 2026. The company has informed the Exchange regarding voting results.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has held its 16th Annual General Meeting through video conferencing, where the company's audited financial statements for the year ended March 31, 2026, were adopted, and a dividend on equity shares for the financial year 2025-26 was declared. The company also appointed a new independent director and ratified the remuneration to the cost auditors for the financial year 2026-27.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has published unaudited financial results for the quarter ended 30th June, 2026, showing a total income from operations of ₹2,149.77 crores and a net profit of ₹221.86 crores.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the link of recording of the post-results conference call held on 4th August, 2026. The audio recording is hosted on the company's website at https://alembicpharmaceuticals.com/quarterly-results.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June 2026, with revenue from operations increasing by 26% YoY to Rs.2150 Cr, and profit after tax at Rs. 173 Cr, up 12% YoY.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter and year ended 30th June 2026. Revenue from operations increased by 26% YoY to Rs.2150 Cr. Profit After Tax at Rs. 173 Cr, up 12% YoY. EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24%. The company has started FY27 on a strong note, delivering broad-based growth across its businesses.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about Investor Presentation on Unaudited Financial Results for the quarter ended 30th June, 2026. The presentation highlights a 26% YoY growth in revenue, with key highlights including a 7% YoY growth in India Branded Business, 49% YoY growth in US Formulation, and 33% YoY growth in R&D. The company also reported a 33% YoY growth in PAT, supported by a strong order book.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has submitted its financial results for the quarter ended June 30, 2026, with the Board of Directors approving the consolidated and standalone unaudited financial results along with the Limited Review Report issued by the Statutory Auditors.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 173.07 crore and revenue from operations of Rs. 2,149.71 crore.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has received USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, a treatment for chronic idiopathic constipation in adults.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has scheduled a post-results conference call on August 4th to discuss Q1 FY27 unaudited financial results.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited's partner NATCO Pharma Limited receives USFDA tentative approval for Olaparib Tablets, 100 mg and 150 mg. This is the 244th ANDA approval for Alembic, with 224 final approvals and 20 tentative approvals.